Fortress Biotech (FBIO)
(Real Time Quote from BATS)
$1.75 USD
+0.02 (1.16%)
Updated Aug 8, 2024 11:38 AM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Fortress Biotech, Inc. [FBIO]
Reports for Purchase
Showing records 281 - 300 ( 317 total )
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
We launch coverage of Fortress Biotech, Inc. with a Buy rating and a $4/ share price target.
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Results; Follow the Numbers as Portfolio Opportunities and Catalysts Grow
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2018 Results; A Plethora of Subsidiary News Should Support Shares; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Mustang Sets up a One-Two Punch for Glioblastoma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Portfolio Model Working, So Should Stock; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2Q18 Results; Subsidiaries Have Been Busy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Avenue Nails First Phase 3; Second to Start in 3Q18
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
1Q18 Results; Important Subsidiary Catalysts Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Additional Phase 1b Analysis Further Highlights CAEL-101 Efficacy as Asset Is Ready to Go Pivotal
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2017 Results; Cranking on More and More Pistons; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Avenue Pivotal Program Expands and Data Not Too Far Off; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Caelum and Mustang Subsidiaries Shine at ASH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Busy Times at Fortress; Important Updates at ASH Shortly; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Dulling the Pain Is Avenue''s Game; Tramadol Phase 3 Gets Rolling; 2Q18 Data Not Too Far Off
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2Q17 Results; Several Subsidiaries Gaining Momentum
Provider: Rodman & Renshaw, Co.
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2Q17 Results; Several Subsidiaries Gaining Momentum
Provider: H.C. Wainwright & Co., Inc.
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage with a Buy rating and $11 price target.
Provider: Rodman & Renshaw, Co.
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
A Growing Portfolio Play in One Fell Swoop; Initiating Coverage at Buy, $11 PT
Provider: H.C. Wainwright & Co., Inc.
Company: Fortress Biotech, Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage to reallocate our research resources.
Provider: Roth Capital Partners, Inc.